Evidence map›Paper›PMID 38106192›Full record

ArticlebioRxiv : the preprint server for biology2023

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of

C K Brierley, B H Yip, G Orlando, H Goyal, S Wen, J Wen, M F Levine, G M Jakobsdottir, A Rodriguez-Meira, A Adamo and 22 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 14 institutions in 4 countries.

B H Yip
G Orlando
H Goyal
S Wen
J Wen
M F Levine
G M Jakobsdottir
A Rodriguez-Meira
A Adamo
M Bashton
A Hamblin
S A Clark
J O'Sullivan
L Murphy
A A Olijnik
A Cotton
S Narina
S M Pruett-Miller
A Enshaei
C Harrison
M Drummond
S Knapper
A Tefferi
I Antony-Debré
S Thongjuea
D C Wedge
S Constantinescu
E Papaemmanuil
B Psaila
J D Crispino
A J Mead
University of Oxford · GBSt. Jude Children's Research Hospital · USOxford Health NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBLudwig Cancer Research · BEMemorial Sloan Kettering Cancer Center · USUniversity of Manchester · GBBeatson West of Scotland Cancer Centre · GBBroad Institute · USCardiff University · GBInserm · FRMayo Clinic in Arizona · USNewcastle University · GBNorthumbria University · GB

Funding

Tissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0M
Cancer Research UK 26988Cancer Research UK 27723NCI NIH HHS P01 CA108671
6 · The paper itself

Abstract

Chromothripsis, the process of catastrophic shattering and haphazard repair of chromosomes, is a common event in cancer. Whether chromothripsis might constitute an actionable molecular event amenable to therapeutic targeting remains an open question. We describe recurrent chromothripsis of chromosome 21 in a subset of patients in blast phase of a myeloproliferative neoplasm (BP-MPN), which alongside other structural variants leads to amplification of a region of chromosome 21 in ∼25% of patients ('chr21amp'). We report that chr21amp BP-MPN has a particularly aggressive and treatment-resistant phenotype. The chr21amp event is highly clonal and present throughout the hematopoietic hierarchy.

Identifiers

PMID38106192
PMCPMC10723394
OpenAlexW4389532382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.